Browsing by Author "Boulware, David R."

Now showing items 1-6 of 6

    • Biomarkers of HIV immune reconstitution inflammatory syndrome 

      Bonham, Shuli; Meya, David B; Bohjanen, Paul R.; Boulware, David R. (Future Medicine, 2008)
      Dysregulation of the immune system drives HIV pathogenesis. As we develop new ways to treat HIV and AIDS, we encounter new clinical ramifications of our treatment on regulatory components of the Immune system. HIV-associated ...

    • Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: A prospective cohort study 

      Boulware, David R.; Meya, David B.; Bergemann, Tracy L.; Wiesner, Darin L.; Rhein, Joshua; Musubire, Paul; Lee, Sarah J.; Kambugu, Andrew; Janoff, Edward N.; Bohjanen, Paul R. (PLoS Medicine, 2010)
      Background: Although antiretroviral therapy (ART) improves survival in persons with cryptococcal meningitis (CM) and AIDS, ART frequently elicits HIV immune reconstitution inflammatory syndrome (IRIS), an exaggerated and ...

    • Integrating cryptococcal antigen screening andpPre-emptive treatment into routine HIV care 

      Rajasingham, Radha; Meya, David B.; Boulware, David R. (Lippincott, Williams & Wilkins, 2012-04-15)
      Cryptococcal meningitis is a leading cause of death in AIDS patients in sub-Saharan Africa. Cryptococcal antigen (CRAG) can be detected weeks before onset of symptoms, and those who are asymptomatic but CRAG positive have ...

    • Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy 

      Kambugu, Andrew; Meya, David B.; Rhein, Joshua; O’Brien, Meagan; Janoff, Edward N.; Ronald, Allan R.; Kamya, Moses R.; Mayanja-Kizza, Harriet; Sande, Merle A.; Bohjanen, Paul R.; Boulware, David R. (CID, 2008)
      Background. Cryptococcal meningitis (CM) is the proximate cause of death in 20%–30% of persons with acquired immunodeficiency syndrome in Africa. Methods. Two prospective, observational cohorts enrolled human immunodeficiency ...

    • Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis 

      Boulware, David R.; Meya, David B.; Conrad, Muzoora; Rolfes, Melissa A.; Hullsiek, Katherine Huppler; Musubire, Abdu; Taseera M., Kabanda; Nabeta, Henry W.; Schutz, Charlotte; Williams, Darlisha A.; Rajasingham, Radha; Rhein, Joshua; Thienemann, Friedrich; Lo, Melanie W.; Nielsen, Kirsten; Bergemann, Tracy L.; Kambugu, Andrew; Munabe, Yukari C.; Janoff, Edward N.; Bohjanen, Paul R.; Meintjes, Graeme (The New England Journal of Medicine, 2014)
      Background Cryptococcal meningitis accounts for 20 to 25% of acquired immunodeficiency syndrome–related deaths in Africa. Antiretroviral therapy (ART) is essential for survival; however, the question of when ART should ...

    • Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis 

      Boulware, David R.; Meya, David B.; Muzoora, Conrad; Rolfes, Melissa A.; Hullsiek, Katherine Huppler; Musubire, Abdu; Taseera, Kabanda; Nabeta, Henry W.; Schutz, Charlotte; Williams, Darlisha A; Rajasingham, Radha; Rhein, Joshua; Thienemann, Friedrich; Lo, Melanie W; Nielsen, Kirsten; Bergemann, Tracy L.; Kambugu, Andrew; Manabe, Yukari C.; Janoff, Edward N.; Bohjanen, Paul R.; Meintjes, Graeme (Massachusetts Medical Society, 2014)
      Background Cryptococcal meningitis accounts for 20 to 25% of acquired immunodeficiency syndrome–related deaths in Africa. Antiretroviral therapy (ART) is essential for survival; however, the question of when ART should ...